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Abstract
Depression is common in Parkinson’s disease and is associated with cognitive impairment.
Dopaminergic medications are effective in treating the motor symptoms of Parkinson’s disease;
however, little is known regarding the effects of dopaminergic pharmacotherapy on cognitive
function in depressed Parkinson patients. This study examines the neuropsychological effects of
dopaminergic pharmacotherapy in Parkinsonian depression. We compared cognitive function in
depressed and non-depressed Parkinson patients at two time-points: following overnight
withdrawal and after the usual morning regimen of dopaminergic medications. A total of 28 non-
demented, right-handed patients with mild to moderate idiopathic Parkinson’s disease participated.
Ten of these patients were depressed according to DSM IV criteria. Results revealed a statistically
significant interaction between depression and medication status on three measures of verbal
memory and a facial affect naming task. In all cases, depressed Parkinson’s patients performed
significantly more poorly while on dopaminergic medication than while off. The opposite pattern
emerged for the non-depressed Parkinson’s group. The administration of dopaminergic medication
to depressed Parkinson patients may carry unintended risks.
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Depression is a common and serious co-morbidity in patients with Parkinson’s disease
(Cummings, 1992; Slaughter et al., 2001; Veazey et al., 2005; Blonder and Slevin, 2011).
Cummings (1992) estimated that approximately 40 percent of PD patients suffer from
depression. A meta-analysis of depression prevalence in PD based on 36 selected studies
found that 17 percent of Parkinson patients had major depressive disorder, 22 percent had
minor depression, and 13 percent were dysthymic (Reijnders et al., 2008). While
Parkinsonian depression may have a reactive component (Gotham et al., 1986; Lindgren,
1996), evidence indicates it is most likely caused by depletion of brain catecholamines and
serotonin and dysregulation of fronto-subcortical connections that regulate mood (Mayberg
et al., 1990; Remy et al., 2005).
Depressed PD patients (dPD) often have cognitive deficits, primarily involving executive
function and working memory. In particular, studies have shown that dPD patients are
impaired relative to non-depressed PD patients on tests of attention and memory, verbal
fluency, set-shifting, confrontation naming, and problem-solving (Starkstein et al., 1989;
Wertman et al., 1993; Troster et al., 1995a; Troster et al., 1995b; Kuzis et al., 1997;
Uekermann et al., 2003; Stefanova et al., 2006). Moreover, depression is associated with
what is now recognized as mild cognitive impairment (MCI) in PD. MCI-PD patients often
have the non-amnestic variety that is characterized by impairments in executive function
(Goldman and Litvan, 2011). In one of the few studies that has explored the effects of
antidepressant medication on cognitive function in Parkinsonian depression, Dobkin et al.
(2010) found no treatment-related improvements in cognition associated with the
administration of the antidepressants paroxetine and nortriptyline, despite successful anti-
depressant effects.
Although the association between cognitive impairment and depression in PD is well-
documented, little is known regarding the effects of dopaminergic medications on cognitive
function in dPD patients. In contrast, numerous studies have suggested that dopaminergic
drugs modulate cognitive processes among PD patients generally. For example,
dopaminergic replacement therapy has been linked to significant, long-lasting improvement
on tests of learning, long-term visual and verbal memory, visuospatial abilities, and frontal
lobe tasks (Kulisevsky et al., 2000). Likewise, levodopa withdrawal is associated with
impaired performance on tests of frontal lobe function, including planning, working
memory, and attentional set-shifting (Lange et al., 1992; Lange et al., 1995; Fournet et al.,
2000). Functional neuroimaging research shows that dopaminergic medications alter
regional brain response during cognitive task performance in PD patients, but these
alterations do not correlate with test performance (Cools et al., 2002; Mattay et al., 2002;
Tessitore et al., 2002). Some studies suggest that dopaminergic medications may enhance or
impair cognitive function in PD depending upon the nature of the task and basal levels of
dopamine (Cools et al., 2001, 2003; Hälbig et al., 2011). In particular, Cools et al. (2003)
report that cognitive inflexibility decreases on dopaminergic therapy while impulsivity
increases. Hälbig et al. (2011) found that PD patients’ performance on emotion recognition
and reaction time tasks was significantly worse while “on” versus “off” dopaminergic
therapy. None of these studies was designed to examine the specific impact of dopaminergic
drugs on cognitive function in Parkinsonian depression, however, and some excluded
patients with a history of affective disorders.
The purpose of the present study was to examine dopaminergic modulation of cognitive and
affective task performance in depressed Parkinson patients. Based on the literature
suggesting that dopaminergic pathways support working memory and affective processing
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and that dopamine agonists may play a role in ameliorating depression in PD (Corrigan et
al., 2000; Rektorová et al., 2003; Lemke, 2008; Barone et al., 2010), our a priori hypothesis
was that withdrawal of dopaminergic medications is associated with increased depressive
mood as well as impairments in cognitive and affective task performance.
2. METHODS
2.1. Subjects
A total of 28 right-handed, non-demented, idiopathic PD patients (10 women, 18 men)
participated in this study. Patients were diagnosed by an American Board of Psychiatry and
Neurology-certified neurologist specializing in movement disorders (JTS) using UK
Parkinson’s Disease Brain Bank Clinical Diagnostic Criteria (Hughes et al., 1992). Only
those patients with a diagnosis of mild to moderate idiopathic PD (≤ 3 on the Hoehn and
Yahr scale) were eligible to participate. Patients were under treatment with levodopa plus
carbidopa either alone or in combination with dopamine agonists. Of the 28 patients, 10 met
DSM-IV diagnostic criteria for a depressive disorder (seven had major depressive disorder,
three had minor depression). Three of the ten dPD patients were taking selective serotonin
re-uptake inhibitors at the time of testing, one patient was also receiving a selective
serotonin-norepinephrine re-uptake inhibitor, and six were not receiving anti-depressant
medication. Demographic and clinical characteristics of the participants are given in Table
1.
Eligible participants made three visits to the University of Kentucky Medical Center to
complete screening and assessment. Prior to either the second or third visit, the patient
stopped taking anti-Parkinson medication after the last dose of the previous evening and
before midnight. Thus testing commenced at minimum nine hours after the last dose of anti-
Parkinson medication. For the other visit, the patient took medication as prescribed the
morning of the session (order counterbalanced across participants). Clinical evaluations
were based on the Unified Parkinson’s Disease Rating Scale (UPDRS) total on and off
scores and UPDRS motor on and off scores. Testing was conducted in an operationally
defined off condition: 1) anti-PD medications withheld for approximately 2.0 times the
duration of each drug’s predicted serum half-life; and 2) prior to the patient’s first dose of
medication on the day of testing. Testing in the on condition was performed within 1–2
hours after a patient’s first dose of anti-PD medication for the day. All participants gave
informed consent under an institutionally approved protocol.
2.2. Procedures
During the first visit participants underwent cognitive screening, the Structured Clinical
Interview for DSM IV, the Hamilton Depression Scale-21 item version (Hedlund and
Viewig, 1979) a neurologic examination, the Hoehn and Yahr Scale, and the Unified
Parkinson’s Disease Rating Scale (UPDRS). The neuropsychological battery, administered
during visits two and three, included the Hopkins Verbal Learning Test-Revised, Purdue
Pegboard, Benton Test of Facial Recognition, Brief Visuospatial Memory Test-Revised,
select subtests of the Delis-Kaplan Executive Function System, Wechsler Adult Intelligence
Scale-Revised, Digit Span Forward and Backward, a facial affect naming task consisting of
validated photos of individuals expressing happy, sad, angry, frightened, disgusted, and
neutral emotions, the Apathy Scale, State-Trait Anxiety Inventory, Geriatric Depression
Scale (15-item version), University of Pennsylvania Smell Test, Visual Analogue ratings of
mood, and the Positive and Negative Affect Scale. The order of tests differed between visits
two and three. We administered alternate test forms when available.
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To compare gender composition as well as the proportion of depressed and non-depressed
PD patients on dopamine agonists, we used the chi-square test. The remaining demographic
and clinical characteristics of depressed and non-depressed PD patients were compared
using two-sampled t tests (see Table 1). Results indicated that there were no statistically
significant differences between the depressed and non-depressed PD groups on gender,
education, or Dementia Rating Scale scaled scores. DPD patients were significantly younger
and scored significantly lower than non-depressed PD patients on the National Adult
Reading Test- revised (NART-R), a measure of pre-morbid intelligence. The following
clinical characteristics did not differ between depressed and non-depressed PD patients:
Hoehn and Yahr stage of illness, the Unified Parkinson Disease Rating Scale Motor or
Tremor subscales, activities of daily living abilities, percent of patients taking dopamine
agonists, and levodopa-equivalent daily dose of medication (Nutt et al., 2003).
As expected, dPD patients were significantly more depressed than non-dPD patients on the
Hamilton Depression and Geriatric Depression Scales (GDS). Depression severity as
measured by the GDS was significantly greater while dPD patients were on dopaminergic
medications as compared to off (6.2 ± 1.0 on PD medications versus 5.2 ± 1.0 off, p =
0.049). There were no statistically significant differences in GDS scores among non-
depressed PD patients on versus off PD medications.
To examine the effect of dopaminergic pharmacotherapy on neuropsychological test
performance as a function of PD mood status, we compared mean response using an analysis
of covariance for a crossover design with depression as the between subjects factor (present
or absent) and dopaminergic medication status as the within subjects factor (on or off),
tested in random order. Age and NART-R Full scale IQ scores served as covariates.
Interactions between depression and medication status were statistically significant for the
facial affect naming test (p=0.016) and the Hopkins Verbal Learning-revised Total Recall
(p=0.011), Delayed Recall (p=0.010), and Recognition/Discrimination sub-scores (p=0.045).
Figure 1 displays least squares means and standard errors for the Facial Affect Naming Test.
Figure 2 displays least squares means and standard errors for Hopkins Verbal Learning-
revised Total Recall and Delayed Recall. The Hopkins Verbal Learning-revised-
Recognition/Discrimination test showed the same pattern of findings as did the other
measures.
4. DISCUSSION
These results indicate that in dPD patients, dopaminergic medications are associated with
poorer performance in verbal memory and affective processing. In particular, dPD patient
report increased depression severity and perform more poorly on tests of verbal memory and
affect recognition while on dopaminergic drugs than while off. Dopaminergic medications
have the opposite effect on memory and affect recognition in non-depressed PD patients in
that performance on these tasks is enhanced by these drugs.
To our knowledge, this is the first report to suggest that dopaminergic medications
universally prescribed to treat Parkinsonian motor symptoms may have deleterious effects
on non-motor function among dPD patients. These negative outcomes do not occur in non-
depressed PD patients; memory and affect recognition improve in non-depressed PD
patients while taking dopaminergic medications. These results underscore the need to
consider depressed and non-depressed PD patients independently in studies designed to
evaluate the effects of dopaminergic pharmacotherapy on cognitive and affective processing
in PD.
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The mechanism underlying these findings remains uncertain. Past research has suggested an
inverted U-shaped relationship between cognitive function and dopamine in the prefrontal
cortex, with both excessive and inadequate levels impairing performance (Cools and
D'Esposito, 2011). Genetic polymorphisms that influence neurotransmitter activity may
contribute to this response. For example, catechol O-methyltransferase (COMT) is an
enzyme that regulates dopamine and other catecholamines in various brain regions. The
COMT gene has a common functional polymorphism (rs4680) that results in a methionine
(met) to valine (val) substitution at codon 158 (Lachman et al., 1996). The low activity met
allele of COMT rs4680 is linked to higher baseline levels of dopamine in the prefrontal
cortex, as well as to enhanced working memory, executive function, attention, and reactivity
to negative emotional stimuli on fMRI (Smolka et al., 2005; Heinz and Smolka, 2006). The
met allele is also associated with a higher risk of depression (Ohara et al., 1998; Aberg et al.,
2011), anxiety (Enoch et al., 2003), bipolar disorder (Mynett-Johnson et al., 1998), and
obsessive compulsive disorder (Karayiorgou et al., 1999), and has been inconsistently linked
to an increased risk of PD as well as variability in individual response to levodopa therapy
(Kunugi et al., 1997; Tai and Wu, 2002; Contin et al., 2005; Kiyohara et al., 2011).
Neuroimaging studies in healthy individuals suggest that the administration of dopamine
modulators such as amphetamine to individuals homozygous for the met allele results in a
decline in cortical efficiency on working memory tasks (Mattay et al., 2003), supporting the
inverted U relationship described above. In contrast, administration of amphetamine to val
homozygotes results in improved cortical efficiency. Although it is premature to suggest that
polymorphisms in genes that control dopamine function during cognitive processing may
underlie the medication effects we observed among dPD patients, this area is worthy of
future research.
This study has identified a serious and previously unreported side-effect of dopaminergic
pharmacotherapy in dPD. Clinicians should be alert to these outcomes and monitor dPD
patients’ cognitive and affective function. However, additional studies in larger samples are
required before these results should be used to alter treatment plans. In particular, future
research should examine (1) the presence of dopaminergic medication-associated increases
in depression severity and their possible relationship to changes in cognitive performance on
and off dopaminergic drugs; (2) the pharmacogenetics underlying these effects, and (3)
alternative medication regimens that will produce consistent cognitive and affective benefit
in both depressed and non-depressed PD patients.
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Figure 1. Dopaminergic Modulation of Facial Affect Recognition
displays a significant interaction between depression and medication status for the facial
affect naming test (p=0.016) after co-varying for age and NART-R Full scale IQ scores.
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Figure 2. Dopaminergic Modulation of Verbal Memory
displays a significant interaction between depression and medication status for the Hopkins
Verbal Learning-revised Total Recall (p=0.019) and Delayed Recall (p=0.010) after co-
varying for age and NART-R Full scale IQ scores.
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Table 1








No. 10 18 NA
% Male 70% 61% NS
Age y, mean (SD) 55.2 (7.0) 68.4 (8.2) 0.0002
Education 15.6 (2.3) 16.0 (3.1) NS
Months since Diagnosis 43.6 (44.0) 55.7 (39.9) NS
NART-R-FSIQ 99.1 (11.8) 107.5 (7.8) 0.0321
DRS-Scaled 12.0 (2.5) 11.0 (2.5) NS
Hamilton Depression 15.0 (4.6) 4.6 (3.7) <0.0001
GDS-15 6.2 (3.4) 1.9 (1.9) 0.0002
Hoehn & Yahr 2.1 (0.5) 2.1 (0.4) NS
UPDRS-Motor 15.0 (6.2) 16.6 (6.3) NS
UPDRS-Tremor 0.9 (1.2) 1.1 (1.7) NS
Schwab-England ADL 84.0 (13.5) 89.2 (11.5) NS
% on DA Agonists 60.0 61.1 NS
Levodopa Equiv daily dose 525.0 (430.9) 513.1 (377.7) NS
NART-R-FSIQ = National Adult Reading Test- revised, full scale IQ;
UPDRS = Unified Parkinson’s Disease Rating Scale
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